Exporter

EN
FR
Codes ATC: J05AG01
EMLc
Indication
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Code ICD11: 1C62.Z
INN
Nevirapine
Type de médicament
Chemical agent
Type de liste
Liste de base (EML)
(EMLc)
Formulations
Oral > Liquid: 50 mg per 5 mL
Oral > Solid > dispersible tablet: 50 mg
Oral > Solid > tablet: 200 mg (EML)
Historique des statuts LME
Ajouté pour la première fois en 1999 (TRS 895)
Modifié en 2002 (TRS 914)
Modifié en 2007 (TRS 950)
Modifié en 2015 (TRS 994)
Modifié en 2023 (TRS 1049)
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Limite d'âge
> 6 weeks
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite sur les brevets.
Wikipédia
DrugBank
Résumé des preuves et recommandation du comité d'experts
The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an“optimal” paediatric formulation.